{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T00:07:45Z","timestamp":1792886865214,"version":"4.5.0"},"reference-count":10,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","prd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Parkinsonism &amp; Related Disorders"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1016\/j.parkreldis.2021.03.007","type":"journal-article","created":{"date-parts":[[2021,3,27]],"date-time":"2021-03-27T04:49:45Z","timestamp":1616820585000},"page":"34-37","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"special_numbering":"C","title":["Effects of angiotensin type 1 receptor antagonists on Parkinson's disease progression: An exploratory study in the PPMI database"],"prefix":"10.1016","volume":"86","author":[{"given":"Lucas","family":"Udovin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matilde","family":"Otero-Losada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofia","family":"Bordet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8017-9458","authenticated-orcid":false,"given":"Guenson","family":"Chevalier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9162-9626","authenticated-orcid":false,"given":"Cecilia","family":"Quarracino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Capani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santiago","family":"P\u00e9rez-Lloret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.parkreldis.2021.03.007_bib1","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1212\/01.wnl.0000247740.47667.03","article-title":"Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030","volume":"68","author":"Dorsey","year":"2007","journal-title":"Neurology"},{"issue":"10","key":"10.1016\/j.parkreldis.2021.03.007_bib2","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1080\/13543784.2017.1371133","article-title":"Renin-angiotensin system as a potential target for new therapeutic approaches in Parkinson's disease","volume":"26","author":"Perez-Lloret","year":"2017","journal-title":"Expet Opin. Invest. Drugs"},{"issue":"1","key":"10.1016\/j.parkreldis.2021.03.007_bib3","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/j.1445-5994.2000.tb01054.x","article-title":"The angiotensin converting enzyme (ACE) inhibitor, perindopril, modifies the clinical features of Parkinson's disease","volume":"30","author":"Reardon","year":"2000","journal-title":"Aust. N. Z. J. Med."},{"issue":"4","key":"10.1016\/j.parkreldis.2021.03.007_bib4","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.pneurobio.2011.09.005","article-title":"Progression marker, the Parkinson progression marker initiative (PPMI)","volume":"95","author":"Parkinson","year":"2011","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.parkreldis.2021.03.007_bib5","series-title":"Guidelines for ATC Classification and DDD Assignment 2012","year":"2011"},{"issue":"3","key":"10.1016\/j.parkreldis.2021.03.007_bib6","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0174379","article-title":"External validation and comparison of two variants of the Elixhauser comorbidity measures for all-cause mortality","volume":"12","author":"Fortin","year":"2017","journal-title":"PloS One"},{"key":"10.1016\/j.parkreldis.2021.03.007_bib7","series-title":"Statistical Power Analysis for the Behavioral Sciences","author":"Cohen","year":"1988"},{"issue":"8","key":"10.1016\/j.parkreldis.2021.03.007_bib8","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1002\/mds.27372","article-title":"C. Movement Disorder Society Evidence-Based Medicine, International Parkinson and movement disorder society evidence-based medicine review: update on treatments for the motor symptoms of Parkinson's disease, Movement disorders","volume":"33","author":"Fox","year":"2018","journal-title":"official journal of the Movement Disorder Society"},{"issue":"6","key":"10.1016\/j.parkreldis.2021.03.007_bib9","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0098961","article-title":"Antihypertensive agents and risk of Parkinson's disease: a nationwide cohort study","volume":"9","author":"Lee","year":"2014","journal-title":"PloS One"},{"issue":"5","key":"10.1016\/j.parkreldis.2021.03.007_bib10","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1001\/jamaneurol.2014.131","article-title":"A randomized clinical trial of high-dosage coenzyme Q10 in early Parkinson disease: no evidence of benefit","volume":"71","author":"Beal","year":"2014","journal-title":"JAMA Neurol"}],"container-title":["Parkinsonism &amp; Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1353802021001000?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1353802021001000?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T00:21:48Z","timestamp":1761178908000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1353802021001000"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":10,"alternative-id":["S1353802021001000"],"URL":"https:\/\/doi.org\/10.1016\/j.parkreldis.2021.03.007","relation":{},"ISSN":["1353-8020"],"issn-type":[{"value":"1353-8020","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of angiotensin type 1 receptor antagonists on Parkinson's disease progression: An exploratory study in the PPMI database","name":"articletitle","label":"Article Title"},{"value":"Parkinsonism & Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.parkreldis.2021.03.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}